Vir Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vir Biotechnology (VIR).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$21Upside to Avg. PT+76.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 11, 2026	Morgan Stanley	Michelle Gilson	PT Raise	Overweight	$23→$27
Jun 3, 2026	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$20→$21
Mar 4, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$15→$20
Feb 25, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$26→$30
Feb 24, 2026	Morgan Stanley	Michelle Gilson	PT Raise	Overweight	$20→$24
Feb 24, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$12→$18
Feb 24, 2026	Needham	Joseph Stringer	PT Raise	Buy	$14→$18
Feb 9, 2026	Needham	Joseph Stringer	Maintained	Buy	$14
Dec 30, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$15
Sep 15, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$15
Sep 3, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$12
Aug 27, 2025	B of A Securities	Geoff Meacham	Upgrade	Neutral→Buy	$12→$14
Jul 11, 2025	Raymond James	Sean McCutcheon	Initiate	Outperform	$12
May 22, 2025	Needham	Joseph Stringer	Maintained	Buy	$14
May 12, 2025	Needham	Joseph Stringer	PT Cut	Buy	$19→$14
Apr 17, 2025	Goldman Sachs	Paul Choi	PT Cut	Buy	$28→$21
Feb 28, 2025	Barclays	Gena Wang	PT Raise	Overweight	$26→$31
Feb 28, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$110
Feb 27, 2025	Needham	Joseph Stringer	Maintained	Buy	$19
Jan 31, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$110

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.

Benzinga Newsdesk

Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.

Benzinga Newsdesk

These Analysts Boost Their Forecasts On Vir Biotechnology

Avi Kapoor

Vir Biotechnology Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Vir Biotechnology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

PRO
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PRO
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30

These Analysts Boost Their Forecasts On Vir Biotechnology

People Also Watch

People Also Watch

Vir Biotechnology Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Vir Biotechnology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

PROLeerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

PROHC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PROBarclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30

These Analysts Boost Their Forecasts On Vir Biotechnology

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

PRO
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PRO
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30